Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Hosted on MSN21h
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.